💊 Fármacos A-Z 🧬 Dianas 🛠 Herramientas 📚 Guías
Todos los fármacos Clases de fármacos Áreas terapéuticas Efectos Secundarios
Guías Glosario Línea de tiempo
Comparaciones Recorridos de fármacos Familias farmacológicas
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Duloxetine

CHEMBL1175 Phase 4 Aprobado Small molecule
Half-Life
12 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
297.4 g/mol
LogP
4.3
Phase
4

Raising the availability of two neurotransmitters at once, duloxetine inhibits the reuptake of both serotonin and norepinephrine, placing it in the serotonin-norepinephrine reuptake inhibitor class. The dual action supports mood while also engaging pain-modulating pathways in the nervous system, which is why the drug treats not only depression and anxiety but also chronic nerve pain and fibromyalgia. A small molecule (C18H19NOS) with a half-life of about 12 hours, it is generally dosed once or twice daily. Its effect on descending pain pathways distinguishes it from antidepressants that act on serotonin alone and underlies its use in painful physical conditions. Duloxetine is an approved medicine bridging psychiatric and pain-related indications.

A serotonin-norepinephrine reuptake inhibitor (SNRI) used to treat depression, anxiety, nerve pain, and fibromyalgia. It works by increasing the availability of serotonin and norepinephrine in the brain.

Peso molecular

297,4150 g/mol

LogP

4,30

TPSA

49,50 Ų

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Cáncer colorrectal Cáncer de mama Cáncer de próstata Diabetes tipo 2 Dolor crónico Enfermedad cardiovascular Enfermedad de Alzheimer Enfermedad del hígado graso no alcohólico Enfermedad de Parkinson Enfermedad infecciosa Enfermedad inflamatoria intestinal Enfermedad por reflujo gastroesofágico Enfermedad pulmonar obstructiva crónica Enfermedad renal crónica Enfermedad respiratoria Epilepsia Esclerosis múltiple Esquizofrenia Ictus Insomnio Lupus eritematoso sistémico Manejo del dolor Migraña Oftalmología Oncología Trastorno bipolar Trastorno de ansiedad generalizada Trastorno depresivo mayor

Clases de fármacos

N — N - Sistema nervioso

Mecanismo de acción

Serotonin-norepinephrine reuptake inhibitor (SNRI).

Pharmacokinetics (PK)

Half-Life 12 hours

Pharmacodynamics (PD)

Mecanismo

Serotonin-norepinephrine reuptake inhibitor (SNRI).

Estructura 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1

                

                

                
                

                    
InChI

                    
InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C18H19NOS

                    

                    
                    

                        
HBD / HBA

                        
1 / 3

                    

                    
                    

                        
Enlaces Rotables

                        
6

                    

                    
                    
                    

                        
Átomos Pesados

                        
21

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            SLC6A4 (Transportador de serotonina)
                            Inhibitor
                        

                        
                        Primary Target
                        
                    

                    
                    

                        

                            CYP2D6 (Citocromo P450 2D6 (CYP2D6))
                            Inhibitor
                        

                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Major


                            
                                Duloxetine + Tramadol
                            
                        

                        
                        
Duloxetine, a serotonin-norepinephrine reuptake inhibitor, combined with tramadol markedly elevates the risk of serotonin syndrome.

                        
                    
                    
                    
                        

                            

  
  Major


                            
                                Duloxetine + Fluoxetine
                            
                        

                        
                        
Fluoxetine is a potent CYP2D6 inhibitor that substantially increases duloxetine plasma levels, while both agents also increase serotonin syndrome risk.

                        
                    
                    
                    
                        

                            

  
  Major


                            
                                Duloxetine + Sertraline
                            
                        

                        
                        
Combining duloxetine and sertraline, two serotonergic antidepressants, markedly increases the risk of serotonin syndrome without added efficacy.

                        
                    
                    
                    
                        

                            

  
  Minor


                            
                                Duloxetine + Pregabalin
                            
                        

                        
                        
Duloxetine and pregabalin are commonly co-prescribed for neuropathic pain with complementary mechanisms; additive CNS effects including dizziness, somnolence, and cognitive impairment can occur.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Duloxetine + Sumatriptan
                            
                        

                        
                        
Duloxetine and sumatriptan co-administration carries a serotonin syndrome risk due to complementary mechanisms of serotonergic stimulation.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Duloxetine + Carbamazepine
                            
                        

                        
                        
Carbamazepine substantially reduces duloxetine plasma levels through CYP1A2 and CYP3A4 induction, risking loss of antidepressant efficacy.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Preguntas frecuentes

                

                    
                    

                        
                        

                            
A serotonin-norepinephrine reuptake inhibitor (SNRI) used to treat depression, anxiety, nerve pain, and fibromyalgia. It works by increasing the availability of serotonin and norepinephrine in the brain.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Serotonin-norepinephrine reuptake inhibitor (SNRI).

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Duloxetine: Half-life: 12 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Duloxetine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Acetaminophen
                            Small molecule
                        
                        
                        
                            Aspirin
                            Small molecule
                        
                        
                        
                            Sertraline
                            Small molecule
                        
                        
                        
                            Escitalopram
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1175.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 60835.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Aviso médico

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.